Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Clinical trial NCT03875235 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03875235
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-16
- Primary completion
- 2021-08-11
- Enrollment
- 810
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.